- Home
- LYFT vs GH Comparison
LYFT vs GH Comparison
Compare LYFT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- GH
- Stock Information
- Founded
- LYFT 2007
- GH 2011
- Country
- LYFT United States
- GH United States
- Employees
- LYFT N/A
- GH N/A
- Industry
- LYFT Business Services
- GH Medical Specialities
- Sector
- LYFT Consumer Discretionary
- GH Health Care
- Exchange
- LYFT Nasdaq
- GH Nasdaq
- Market Cap
- LYFT 6.3B
- GH 4.9B
- IPO Year
- LYFT 2019
- GH 2018
- Fundamental
- Price
- LYFT $16.10
- GH $50.00
- Analyst Decision
- LYFT Buy
- GH Strong Buy
- Analyst Count
- LYFT 33
- GH 20
- Target Price
- LYFT $16.53
- GH $54.35
- AVG Volume (30 Days)
- LYFT 14.2M
- GH 2.1M
- Earning Date
- LYFT 08-06-2025
- GH 08-06-2025
- Dividend Yield
- LYFT N/A
- GH N/A
- EPS Growth
- LYFT N/A
- GH N/A
- EPS
- LYFT 0.14
- GH N/A
- Revenue
- LYFT $5,958,987,000.00
- GH $773,996,000.00
- Revenue This Year
- LYFT $14.15
- GH $23.14
- Revenue Next Year
- LYFT $12.81
- GH $21.42
- P/E Ratio
- LYFT $117.41
- GH N/A
- Revenue Growth
- LYFT 27.32
- GH 28.20
- 52 Week Low
- LYFT $8.93
- GH $20.14
- 52 Week High
- LYFT $19.07
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- LYFT 59.28
- GH 60.59
- Support Level
- LYFT $15.58
- GH $48.07
- Resistance Level
- LYFT $16.46
- GH $53.42
- Average True Range (ATR)
- LYFT 0.54
- GH 2.25
- MACD
- LYFT 0.05
- GH -0.12
- Stochastic Oscillator
- LYFT 86.47
- GH 55.56
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.